Speaker Profile
VP of Sales, Alamar Biosciences
Biography
Alex Forrest-Hay has 24 years experience working in the genomics, proteomics, metabolomics industry with a passion for personalized medicine. He has held a variety of sales and business development leadership positions and was most recently at Seer Bio where he led the commercial roll out of the nanoparticle based Proteograph proteomics technology. Prior to Seer, Alex spent 5 years in the metabolomics sector with Metabolon and Nightingale Health. Alex worked for Affymetrix for 9 years prior and spent 3 of those years developing and launching clinical RNA biomarker assays to enable accurate diagnosis of cholangiocarcinoma, head and neck cancer and lymphoma. Alex was also at Beckman Coulter for 7 years developing clinical genomics assays and supporting pioneering DNA sequencing developments. Prior to Beckman Coulter, he worked as a researcher exploring the genetics of astrocytomas at the University of Keele.
Talk
NULISA: A Novel Ultra-Sensitive and High-Multiplex Proteomic Platform
The proprietary NULISA Platform utilizes a novel sequential capture and release method reducing background signal and increasing sensitivity and dynamic range compared with standard approaches. The NULISA Platform allows for a fully automated workflow with the ARGO HT System enabling
Clinical Dx Showcase:
Alamar Biosciences
Alamar Biosciences offers fully automated, high throughput solutions for ultra-high sensitivity protein biomarker analysis across a range of multiplex levels in liquid biopsy samples with their NULISA™ Platform and ARGO™ HT System.
Session Abstract – PMWC 2024 Silicon Valley
The PMWC 2024 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
